Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

67.45 +0.21 (+0.31%)
Streaming Delayed Price Updated: 10:14 AM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
US Stocks Start Week On Lower Note, Dow Drops Over 100 Points
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 100 points on Monday. 
Via Benzinga
UK Study Finds Pfizer/Bristol Myers Clotting Drug Does Not Help COVID-19 Patients
According to a U.K. trial, Eliquis (apixaban), widely prescribed for COVID-19, did not help patients recovering from moderate and severe COVID. The drug used after discharge from the hospital does not... 
Via Benzinga
3 Dividend Stocks to Hold Forever
These businesses -- and dividends -- are built to last. 
Via The Motley Fool
Is Now the Time for Income Investors to Buy This Big Pharma Stock?
This drugmaker is among the most dominant pharmaceutical companies in the world. 
Via The Motley Fool
Mirati Therapeutics Surges As Big Pharma Reportedly Preps For A Buyout Battle
There are reportedly numerous companies in the mix and they're all awaiting data next month. 
Via Investor's Business Daily
Where Bristol-Myers Squibb Stands With Analysts
 
Via Benzinga
8 Analysts Have This to Say About Bristol-Myers Squibb
 
Via Benzinga
2 Ultra-Safe Passive Income Stocks to Buy Right Now
These two top biopharma stocks are crushing the 2022 bear market. 
Via The Motley Fool
2 Reasons to Buy AbbVie Stock and 1 Reason to Sell
The pharmaceutical company's golden goose is about to stop laying golden eggs, but that won't be a permanent problem. 
Via The Motley Fool
Southwest Gas, Albemarle, Bristol-Myers Squibb And This Fintech Play On CNBC's 'Final Trades'
On CNBC’s “Halftime Report Final Trades,” Karen Firestone of Aureus Asset Management said HealthEquity Inc. (NASDAQ: HQY) is “a stock that provides leadership in the health savings plan” segment. 
Via Benzinga
Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved
This year, the World Health Organization (WHO) announced that cancer has become the leading cause of death worldwide, with the latest data showing that nearly 10 million deaths in 2020 were the result... 
Via Benzinga
Credit Suisse Sees Uncertainty On New Product Launch Execution & Growth For Bristol Myers
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
Upgrades 
Via Benzinga
Peering Into Bristol-Myers Squibb's Recent Short Interest
Bristol-Myers Squibb's (NYSE:BMY) short percent of float has risen 8.33% since its last report. The company recently reported that it has 24.77 million shares sold short, which is 1.17% of all regular... 
Via Benzinga
2 Stocks to Buy Whether or Not a Recession Is Coming
Both have outperformed the stock market this year. 
Via The Motley Fool
OncoSec Touts Encouraging Early Data For Opdivo Combined Immunotherapy For Skin Cancer
 
Via Benzinga
JPMorgan Chase, Bristol-Myers Squibb And 3 Other Stocks Insiders Are Selling
US crude oil futures traded lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Why Are Healthcare Stocks Down Today?
Healthcare stocks are falling after a false tweet from a Twitter account impersonating Eli Lilly. Here's what this news means for investors. 
Via InvestorPlace
Is This Blue-Chip Dividend Stock a Buy?
Shares of this pharmaceutical stock have surged higher in 2022. 
Via The Motley Fool
SELLAS Life Sciences' GPS Combo Therapy Shows Overall Survival Of 18 Months In Pretreated Ovarian Cancer Patients
 
Via Benzinga
Bristol-Myers Squibb To Surge Over 10%? Plus Morgan Stanley Predicts $263 For L3Harris Technologies
Atlantic Equities boosted the price target on Bristol-Myers Squibb Company (NYSE: BMY) from $85 to $88. Atlantic Equities analyst Steve Chesney maintained the stock with an Overweight. Bristol-Myers... 
Via Benzinga
Buy Bristol-Myers Squibb, Merck, 10-Year Treasury ETF And This Payments Stock: CNBC's 'Final Trades'
On CNBC’s “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners chose Bristol-Myers Squibb Co. (NYSE: BMY) as his final trade. 
Via Benzinga
Here's Why This Growth Stock Is Already My 2022 Winner
Despite a challenging year for the markets, this growth stock managed to stand out with another stellar quarter. 
Via The Motley Fool
The 7 Best Pharma Stocks to Buy Now
Investors searching for gains in the current market storm should consider taking a position in some of the best pharma stocks. 
Via InvestorPlace
Investing $1,000 in the Current Market? Don't Overlook These 2 Winning Dividend Stocks
Just because the stock market is going haywire doesn't mean you have to sit on the sidelines. 
Via The Motley Fool
US Supreme Court Throws Out Bristol Myers Appeal On Cancer-Drug Related Patent With Gilead
 
Via Benzinga
A $10,000 Investment at the Start of the Great Recession Would Be Worth This Much Today
Investors should focus on individual businesses -- not economic predictions -- when making investment decisions. 
Via The Motley Fool
How Is The Market Feeling About Bristol-Myers Squibb?
Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 4.42% since its last report. The company recently reported that it has 23.08 million shares sold short, which is 1.08% of all regular... 
Via Benzinga
Can Biotech Stocks Continue Rallying In This Bear Market?
Via Talk Markets
After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.